CNS Pharmaceuticals, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $6.2M | $5.0M |
| FY2022 | — | $8.1M | $10.1M |
| FY2023 | — | $-4.4M | $548.7K |
| FY2024 | — | $6.2M | $6.5M |
| FY2025 | — | $4.5M | $7.2M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $6.2M | $5.0M |
| FY2022 | — | $8.1M | $10.1M |
| FY2023 | — | $-4.4M | $548.7K |
| FY2024 | — | $6.2M | $6.5M |
| FY2025 | — | $4.5M | $7.2M |